Caribou Biosciences 2025 Q1 Earnings Misses Targets with 3% Net Loss Improvement

Caribou Biosciences (CRBU) reported its fiscal 2025 Q1 earnings on May 08th, 2025. The company missed expectations with a 3% decrease in revenue compared to the previous year. Despite this, Caribou managed to narrow its net loss, showing a modest improvement in its earnings per share. The company maintained its guidance, expecting strong clinical data from its lead programs later this year, which could influence future financial performance.

Revenue

Caribou Biosciences reported a total revenue of $2.35 million for Q1 2025, marking a decrease of 3.1% compared to $2.43 million in Q1 2024.

Earnings/Net Income

Caribou Biosciences narrowed its losses, reporting a net loss of $39.99 million in Q1 2025, which marks a 3.0% reduction from the $41.23 million loss in Q1 2024. The EPS also improved from a loss of $0.46 per share in 2024 to $0.43 in 2025, indicating a modest improvement.

Price Action

The stock price of Caribou Biosciences has edged up 0.64% during the latest trading day, has edged down 1.47% during the most recent full trading week, and has climbed 4.30% month-to-date.

Post Earnings Price Action Review

Investors employing a strategy of buying Caribou Biosciences shares after a quarter-over-quarter revenue drop and holding for 30 days experienced moderate results. Over the past five years, this strategy yielded an annualized return on investment of -41.53%, reflecting significant losses and low profitability. However, it managed to outperform the broader buy-and-hold approach, delivering excess returns of 32.24%. Despite the negative ROI, the strategy's superior performance relative to the buy-and-hold method suggests its potential for delivering higher returns amid the company's ongoing financial challenges. Yet, investors must remain cautious, considering the overall volatility and historical performance of CRBU shares.

CEO Commentary

“Caribou’s two lead Phase 1 clinical programs, CB-010 for large B cell lymphoma and CB-011 for multiple myeloma, continue to demonstrate encouraging efficacy and have the potential to benefit individuals living with hematologic malignancies,” said Rachel Haurwitz, PhD, President and CEO. The company remains focused on delivering off-the-shelf allogeneic CAR-T cell therapies, aiming for broad access and rapid availability to patients and healthcare systems. Strategic prioritization of resources has been implemented to enhance focus on these lead oncology programs, reflecting a commitment to navigating current challenges while positioning for growth.

Guidance

Caribou anticipates presenting robust clinical datasets from CB-010 and CB-011 in H2 2025, with cash reserves projected to fund operations into H2 2027. The company expects to provide initial safety and efficacy data for the confirmatory cohort of CB-010 alongside pivotal trial design updates, contingent on positive outcomes and FDA alignment. For CB-011, Caribou plans to share dose escalation data and recommend doses for expansion, aiming for a comprehensive update on patient outcomes in the same timeframe.

Additional News

Caribou Biosciences recently announced participation in the BofA Securities 2025 Health Care Conference, where CEO Rachel Haurwitz will deliver a presentation on May 13th. The company also implemented strategic pipeline prioritization, focusing on its lead oncology programs, CB-010 and CB-011. This shift resulted in a 32% workforce reduction, extending cash runway into H2 2027. Additionally, Caribou appointed Sri Ryali as Chief Financial Officer, bringing experienced leadership to navigate the company's financial operations. Lastly, Caribou filed for a mixed shelf offering of up to $300 million, signaling potential fundraising activities to support its clinical-stage programs and strategic objectives.